Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $120.08 Average Price Target from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $120.0833.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Morgan Stanley restated an “overweight” rating and issued a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th.

Monopar Therapeutics Price Performance

Shares of MNPR stock opened at $96.47 on Wednesday. The business has a 50-day moving average price of $111.72 and a two-hundred day moving average price of $80.90. The firm has a market cap of $647.51 million, a P/E ratio of -44.46 and a beta of 1.49. Monopar Therapeutics has a 12-month low of $50.07 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. As a group, research analysts expect that Monopar Therapeutics will post -2.98 EPS for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In related news, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director owned 23,751 shares of the company’s stock, valued at $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares of the company’s stock, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.70% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new stake in shares of Monopar Therapeutics in the second quarter worth $7,124,000. Walleye Capital LLC bought a new position in Monopar Therapeutics in the first quarter valued at about $3,458,000. Siren L.L.C. boosted its position in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares during the last quarter. Bank of America Corp DE grew its position in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the period. Finally, ADAR1 Capital Management LLC increased its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.